

For Immediate Release

September 30, 2025

Company Name : AI KEN PHARMA ASIA PACIFIC HOLDINGS PTE. LTD.

Representative : Kentaro Imamoto, President & CEO

Contact : info.ap@aikenpharma.com

**Regarding the Memorandum of Understanding with Alfresa Holdings Corporation on
Joint Business Development in Southeast Asia and the Commencement of
Discussions toward a Capital and Business Alliance**

We are pleased to announce that we have entered into a Memorandum of Understanding (“MOU”) with Alfresa Holdings Corporation (Head Office: Chiyoda-ku, Tokyo; President & CEO: Ryuji Arakawa; hereinafter “Alfresa”) on the joint development of businesses centered on ethical pharmaceuticals in Southeast Asia, and have commenced discussions toward a capital and business alliance, as outlined below.

1. Background and Purpose

Our company is the first Japanese broad-based pharmaceutical wholesaler in Southeast Asia. Guided by our vision, “*A Japanese Bridge for Healthcare Needs in Asia*”, we are engaged in the wholesale distribution of pharmaceuticals and medical devices—particularly in the fields of oncology and gastroenterology—in Cambodia and Laos. Our regional holding headquarters in Singapore provides strategic support, business development, financial management, quality assurance and pharmacovigilance, and governance oversight to our subsidiaries.

The Alfresa Group established Alfresa Codupha Healthcare Vietnam Co., Ltd. (Head Office: Ho Chi Minh City, Vietnam; General Director: Tomomasa Takasago; hereinafter “Alcophia”) in November 2013. In Vietnam, the company contributes to the healthcare sector by introducing products and services not previously available and operates an import and sales business of healthcare-related products, primarily medical devices and medical supplies.

Through this MOU, both parties will collaborate to strengthen the supply system for pharmaceuticals and medical devices in the Southeast Asian market. For Japanese pharmaceutical companies, this initiative will secure reliable distribution channels for expansion into Southeast Asia, while for local medical institutions, it will enhance the quality and accessibility of healthcare.

2. Content of Discussions

Our company and Alfresa will advance discussions toward a capital and business alliance, while also jointly promoting proposals to Japanese pharmaceutical and medical device manufacturers considering entry into Southeast Asia.

3. Overview of Alfresa Holdings Corporation

- **Name:** Alfresa Holdings Corporation
 - **Location:** 1-1-3 Otemachi, Chiyoda-ku, Tokyo
 - **Representative:** Ryuji Arakawa, President & CEO
 - **Business Activities:** Management of subsidiaries engaged in the wholesale distribution, manufacture and sale, and import/export of pharmaceuticals, clinical diagnostics, medical devices and supplies, as well as the operation of dispensing pharmacies and other related businesses
 - **Established:** September 29, 2003
 - **Stock Exchange Listing:** Tokyo Stock Exchange Prime Market (Code: 2784)
-

End